Beilu was Awarded the Title of A-class enterprise for safety production

2023/01/31

Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this award for two consecutive years.

/uploads/image/2023/01/31/beilupharma-20230131-1.jpg

Beilu Pharmaceutical has always been conscientious in fulfilling its corporate responsibility, implementing a series of important plans on production safety, and actively carrying out safety work to prevent accidents from occurring.

References

Related News

Invitation Letter
May 9, 2025Beilu pharma is delighted to to extend a warm invitation to you to make an appointment in CPHI China June 24-26 at Shanghai.Our Booth Number is E3A49.view
Hichi Pharmaceutical's Iodixanol API Approved for Market
September 9, 2024Iodixanol is the active pharmaceutical ingredient for iodixanol injection, a contrast agent used for intrathecal contrast, cardiovascular angiography, and intravenous urography. Its mechanism of actio...view
Introduction of Intravenous Contrast Media
December 27, 20211. The concept of intravenous contrast mediaThere are many types of contrast medium in the clinic, and different types of contrast medium will produce different feelings after they are injected into p...view
Beilu Pharmaceutical's Repaglinide Tablets Receive Generic Drug Bioequivalence Assessment
June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view
Beilu Pharmaceutical's Sees Strong Start to 2025 with Q1 Revenue and Profit Growth
April 25, 2025Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2...view
Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch
July 2, 2025Recently, Hichi Pharmaceutical's Iopromide API has received the "Approval Notice for the Marketing Application of Chemical Raw Materials" from the National Medical Products Administratio...view